CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 18 enrolled
Drug / intervention
BIA 9-1067 +1 moredrug
Likely dose
Sinemet® 100/25 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01533077
NCT01533077Phase 1Completed
CompareCT.gov

Pharmacokinetic Interaction Between BIA 9-1067 and Standard-release Levodopa/Carbidopa in Healthy Subjects

Bial - Portela C S.A.·interventional·Posted Feb 15, 2012·Updated Dec 22, 2015

In Brief

A Phase 1 clinical trial evaluating BIA 9-1067 and Sinemet® 100/25 mg for Parkinson Disease. Completed, enrolled 18 participants across 1 site.

Detailed Summary

To investigate the pharmacokinetics of levodopa when administered concomitantly with BIA 9-1067 or 1 hour after.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsParkinson Disease
CountriesCanada
Collaborators--

Timeline

Phase 1CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedFeb 15, 2012
Enrollment StartMar 1, 2009
Primary CompletionOct 1, 2009
Study CompletionFeb 1, 2010
TodayJul 2, 2026
Enrollment to primary: 7 monthsPosted 14.4 years ago

Interventions

BIA 9-1067drug

50 mg of BIA 9-1067 (single-dose)

Sinemet® 100/25 mgdrug

immediate-release levodopa/carbidopa 100/25 (single-dose).